Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic antigens recognized by pooled human immunoglobulin G (IgG) encompass a vast array of molecular structures from bacteria, viruses, and other pathogens that are specifically bound by the Fab (fragment antigen-binding) regions of antibodies (StatPearls, 2023). These antigens include viral capsid proteins, bacterial surface polysaccharides, and exotoxins, such as those produced by Streptococcus pneumoniae or Clostridium tetani (NCBI, 2022). The interaction between the Fab regions of pooled IgG and these antigens is the primary mechanism for providing passive immunity in patients with primary or secondary immunodeficiencies. By binding to these targets, the antibodies neutralize viral infectivity, inhibit bacterial adherence to host tissues, and promote opsonization, which facilitates pathogen clearance by phagocytic cells (Journal of Clinical Immunology, 2018). Furthermore, pooled IgG contains antibodies that can neutralize superantigens, thereby preventing the massive, non-specific T-cell activation and cytokine release associated with certain severe infections (Frontiers in Immunology, 2020). This broad-spectrum recognition is achieved by pooling plasma from thousands of healthy donors, ensuring a diverse repertoire of antibody specificities.
The Fab regions of pooled IgG bind to specific epitopes on pathogenic antigens, leading to neutralization of toxins and viruses, inhibition of microbial attachment to host cells, and opsonization for phagocytosis by macrophages and neutrophils.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic antigens recognized by pooled human immunoglobulin G.